Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels

dc.contributor.authorRivkina, A.
dc.contributor.authorVitols, G.
dc.contributor.authorMurovska, M.
dc.contributor.authorLejniece, S.
dc.date.accessioned2018-06-19T10:43:08Z
dc.date.available2018-06-19T10:43:08Z
dc.date.issued2011
dc.description.abstractSerum thymidine kinase (TK), zeta-associated protein of 70 kDa (ZAP-70) and CD38 levels have been shown to be correlated with survival in chronic lymphocytic leukaemia (CLL). Aim: To investigate the possible correlations between TK, ZAP-70 and CD38 levels as prognostic markers in new diagnosed Rai stages of CLL patients. Methods: 120 CLL patients were enrolled. ELISA was used to measure serum TK level, flow cytomerty — to determine ZAP-70 and CD38 expression applying ZAP-70 Kit and monoclonal antibody to CD38, respectively. Results: Significantly higher levels of TK were found in the high progression group of CLL patients that corresponded to stage II (Rai classification). An elevated level of TK, CD38 and ZAP-70 together was also found in the II stage. The coefficient of correlation between CD38 and ZAP-70 is reliable (p < 0.001). There is also a correlation between the level of TK and the disease stage (p < 0.05). Other parameters do not show this correlation. Conclusion: The determination of TK, ZAP-70 and CD38 together allows patients susceptible to a possible stage of the disease, to be identified. Estimation of the factors at an early stage of the disease may allow an earlier commencement of treatment.uk_UA
dc.identifier.citationIdentifying the stage of new CLL patients using TK, ZAP-70, CD38 levels / A. Rivkina, G. Vitols, M. Murovska, S. Lejniece // Experimental Oncology. — 2011. — Т. 33, № 2. — С. 99-103. — Бібліогр.: 30 назв. — англ.uk_UA
dc.identifier.issn1812-9269
dc.identifier.urihttps://nasplib.isofts.kiev.ua/handle/123456789/138626
dc.language.isoenuk_UA
dc.publisherІнститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН Україниuk_UA
dc.relation.ispartofExperimental Oncology
dc.statuspublished earlieruk_UA
dc.subjectOriginal contributionsuk_UA
dc.titleIdentifying the stage of new CLL patients using TK, ZAP-70, CD38 levelsuk_UA
dc.typeArticleuk_UA

Файли

Оригінальний контейнер

Зараз показуємо 1 - 1 з 1
Завантаження...
Ескіз
Назва:
02-Rivkina.pdf
Розмір:
126.27 KB
Формат:
Adobe Portable Document Format

Контейнер ліцензії

Зараз показуємо 1 - 1 з 1
Завантаження...
Ескіз
Назва:
license.txt
Розмір:
817 B
Формат:
Item-specific license agreed upon to submission
Опис: